OBM Transplantation (ISSN 2577-5820) is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc., which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.

OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.

We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor. 


Publication Speed (median values for papers published in 2023): Submission to First Decision: 6.7 weeks; Submission to Acceptance: 14.4 weeks; Acceptance to Publication: 6 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017
Open Access Review

Nutritional Management for Infants and Children Pre and Post-Liver Transplant

Melissa Mortensen 1, *, Christine Lundberg 2, Simon Horslen 3, 4

1. Clinical Nutrition, Seattle Children's Hospital, Seattle, United States

2. Pediatric Transplant Surgery, Seattle Children's Hospital, Seattle, United States

3. Division of Gastroenterology, Seattle Children’s Hospital, Seattle, United States

4. Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA

Correspondence: Melissa Mortensen

Academic Editor: Mohammed Moghadasian

Special Issue: Diets and Transplantation

Received: December 05, 2018 | Accepted: July 08, 2019 | Published: July 17, 2019

OBM Transplantation 2019, Volume 3, Issue 3, doi:10.21926/obm.transplant.1903073

Recommended citation: Mortensen M, Lundberg C, Horslen S. Nutritional Management for Infants and Children Pre and Post-Liver Transplant. OBM Transplantation 2019; 3(3): 073; doi:10.21926/obm.transplant.1903073.

© 2019 by the authors. This is an open access article distributed under the conditions of the Creative Commons by Attribution License, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited.


Background: Infants and children undergoing liver transplant require ongoing nutritional evaluation throughout the pre and post-transplant period. The pathophysiologic causes of chronic liver disease and acute liver failure are varied, and each present different and unique nutritional challenges.

Methods: A review of the literature and Seattle Children's established guidelines for nutritional management of pediatric liver transplant patients was conducted.

Results: We present guidelines of care to optimize nutrition status of infants and children in the pre and post-transplant phases.

Conclusion: While malnutrition is common in the child with liver failure, it is also treatable when approached with a multidisciplinary focus on identification of clinical symptoms.


Pediatrics; liver transplant; nutrition

1. Introduction

Liver disease in the infant or child involves irreversible changes in the hepatic structure leading to symptoms including, but not limited to, liver cirrhosis, cholestasis and jaundice, hepatosplenomegaly and ascites, pruritus with disruptions of sleep leading to decreased quality of life, and malnutrition [1]. The degree of malnutrition in the infant or child with liver disease plays a significant role in their health and stability pre-transplant, ability to heal and recover immediately post-transplant, and thrive in the months and years after liver transplant. Malnutrition in chronic liver disease leads to decreased neurocognitive development and growth, and is a predictor of suboptimal outcomes post-transplant, leading to increased morbidity and mortality [2].

A multidisciplinary approach is required to manage the prevention and treatment of malnutrition in the pediatric patient with liver disease requiring transplantation. Optimizing growth and nutrition status before transplant helps to minimize post-transplant complications such as stunting, delayed healing, laboratory abnormalities and disordered eating [1].The causes of liver disease in pediatrics and indications for transplant, nutritional care in the pre and post-transplant settings, and long-term management to avoid complications of poor growth and malnutrition is described here. This article serves as a concise reference for liver transplant teams. We reviewed up to date literature that focused on pre-transplant nutrition and/or post-transplant nutrition.

2. Indications for Liver Transplant in Childhood

The indications for referring and ultimately listing a child for liver transplantation can be condensed to four basic groups, namely acute liver failure, chronic liver failure, unresectable tumor in the liver and liver-based inborn errors of metabolism. In these metabolic conditions, the enzyme defect results in injury to other organs away from the liver. Further injury can be prevented by liver transplantation because the deficient metabolic pathway is located within the liver.

Acute liver failure is defined as loss of liver functions over a period of days to a few weeks, having previously had no evidence of liver disease. This loss of function may manifest clinically as jaundice, bleeding and encephalopathy. Causes include toxicity from medications (most commonly acetaminophen overdose), herbals and other environmental chemicals, viral infections, autoimmune liver disease and, particularly in children, liver failure of unknown cause [3].

Chronic liver disease results from a wide range of congenital and acquired conditions that gradually erode the function of the liver, most often due to progressive fibrosis resulting eventually in cirrhosis. At this stage, portal hypertension with all the potential complications such as encephalopathy, variceal hemorrhage and ascites may occur. Additionally, synthetic function of the liver may fail with worsening jaundice and coagulopathy. Therefore, there are two basic indications for liver transplantation in children with chronic liver disease: i) liver failure, where the function of the liver deteriorates to a point where death will occur if the liver is not transplanted, and ii) where complications of the disease make the quality of life unacceptable such as growth impairment, gastrointestinal bleeding or severe and uncontrollable itching.

In children, the most common cause of chronic liver failure is biliary atresia, a condition that affects infants in the first two months of life and results in complete obliteration of the biliary system [4,5]. The precise cause or causes of biliary atresia are not known. An operation originally described by the Japanese surgeon Morio Kasai, a hepatoportoenterostomy, can, if done early enough and by the appropriately skilled team, alleviate or prevent progression of the fibrosis. However, in many infants the operation does not result in good bile flow and cirrhosis ensues. Other causes of chronic liver disease in children include genetic defects such as Alagille syndrome and the various types of progressive familial cholestasis. Autoimmune diseases such as autoimmune hepatitis and primary sclerosing cholangitis primarily affect older children and adolescents. Although liver tumors are far less common than in adults, both malignant and benign tumors of the liver may necessitate transplantations. Unlike in adults where hepatocellular carcinoma associated with chronic liver fibrosis accounts for the majority of malignant tumors going to liver transplant, in children hepatoblastoma is by far the most common indication. Many hepatoblastomas are able to be fully removed with liver resection but a proportion involve too much of the liver to allow for anything other than total hepatectomy and transplant. It is imperative when considering transplantation that there is no extrahepatic metastatic spread or complete clearance of metastases prior to transplantation. There are a variety of other rare tumors that can be managed with transplantation of the liver but detailed discussion is beyond the scope of this chapter.

Lastly, there is a group of conditions where single metabolic pathways in the liver are defective due to genetic mutations [6]. Some result in direct liver injury, such as alpha-1 antitrypsin deficiency and Wilson disease, and evaluation of these patients is based on the considerations for acute or chronic liver disease described above. Other liver-based metabolic defects, however, do not directly damage the liver but lead to injury to other tissues and organs. Liver transplantation has been shown to prevent further injury, although it will not reverse damage already established. For example, neurological injury can occur in urea cycle disorders due to accumulation of ammonia, in organic acidemias, in Maple Syrup Urine Disease (MSUD) because of acidosis and metabolic decompensation and in Crigler-Najjar because of bilirubin encephalopathy. See Table 1 for examples of metabolic liver diseases.

The nutritional assessment and interventions will clearly vary depending on the primary diagnosis and careful monitoring is needed for all infants and children considered for liver transplantation. In addition, both dietitians and medical teams should have the knowledge and expertise to manage such patients optimally, recognizing the importance of nutrition to transplant outcomes.

Table 1 Examples of metabolic liver diseases in children [6].

3. Pre-Transplant Nutrition Care: Preventing and Resolving Malnutrition in a Multidisciplinary Model

Infants, children and adolescents with end stage chronic liver disease are the patients at greatest risk of malnutrition. The cause is multifactorial, including poor liver synthetic function, decreased appetite, portal hypertensive enteropathy leading to malabsorption, increased metabolic demands, encephalopathy and GI bleeding. Malnutrition is a particular risk to the youngest patients (age less than 2 years), those with cholestasis, and those with significant sequelae of hepatic dysfunction such as ascites and varices (Figure 1A). Malnutrition is associated with poor post-operative outcomes after transplantation, including increased mortality [7] and increased hospital length of stay [8]. Earlier papers focused on pre- & post-transplant survival, but as progress is made in caring for these patients, current research now describes increased morbidity associated with malnutrition and not just mortality [2]. It is important for early identification of malnutrition in infants and children to provide timely intervention, thus optimizing outcomes. Transplant teams are encouraged to optimize linear growth in children pre transplant as evidence indicates this is predictive of post-transplant catch up within the first 2 years [9]. Each patient undergoes a multidisciplinary evaluation, including hepatologist, surgeon, nurse coordinator, pharmacist, social worker, and dietitian; all are stakeholders in optimizing transplant outcomes.

While understanding the disease progression for each diagnosis is important, ultimately nutrition screening by the team transplant dietitian contains the following same principles [1]. Nutritional status is determined with nutrition focused physical assessments, including anthropometrics such as mid-upper arm circumference (MUAC) and triceps skinfold (TSF), as well as biochemical indices. The dietitian has the most comprehensive knowledge of dietary interventions, dietary products available to facilitate the interventions, feeding methods and ongoing monitoring of responses to nutritional intervention. The transplant dietitian leads the nutrition plan of care to preserve or improve growth potential and minimize post-transplant complications regardless of the cause for ESLD.

3.1 Guidelines for Nutrition Support

Maintaining adequate nutrition orally may be challenging for infants and children with organomegaly, ascites, fatigue and malabsorption with progressive liver disease. Enteral nutrition infused continuously via nasogastric (NG) tube is beneficial if recurrent emesis is related to hepatosplenomegaly resulting in decreased ability for the stomach to expand to hold a bolus. For infants, breast milk is preferred if available for all the documented benefits [10]. Formula or fortified breast milk is concentrated to meet calorie goals to a maximum of 30 kcal/oz. A formula high in medium chain triglyceride (MCT) content is preferred (30-70% fat kcal as MCT) in infants and children with cholestasis as short to medium chain fats are less dependent on bile acids for absorption. Please see Table 2 for energy and protein recommendations. At Seattle Children's, our standard is to start at 120kcal/kg. Some malnourished infants need >140-150 kcal/kg [2,8]. Calorie provision is increased as indicated by growth parameters and anthropometrics. If feeding via a nasogastric tube, providing opportunities for oral stimulation to maintain skills and prevent oral aversion is essential in preparation for post-transplant transition back to oral autonomy.

Table 2 Estimated enteral energy and protein needs in the setting of cholestatic liver disease (general starting guidelines per our institution, with evidence indicating at least 1.3-1.5 x RDA for energy needs) [1,8].

Parenteral nutrition (PN) is effective for improving nutrition status while on the transplant waiting list, and even in resolving malnutrition in some patients prior transplant [2,11,12]. PN is not favored as a treatment approach at all transplant centers for multiple reasons, such as the cost versus enteral feeds, risk of complications from central line access, complexity of PN orders resulting in opportunity for prescription errors, and PN component shortages requiring rationing or suboptimal substitutions. However, PN has been utilized successfully by transplant centers familiar with outpatient PN management, and this has been the experience at Seattle Children's for infants and toddlers with severe malnutrition not thriving on optimized enteral feeds. Fewer calories are required intravenously and fluids needed to meet goals are generally less than enteral formulas [8]. Thus, parenteral nutrition can also be beneficial in the setting of fluid restriction for ascites management. Refer to Table 3 below for energy, protein and fluid recommendations for this cohort to meet 100% estimated nutrition needs. If a patient requires parenteral nutrition, NG feeds are discontinued while the NG tube may remain in place for medication administration, but feeds are still offered by mouth to maintain oral skills as discussed above. PN is often maximally concentrated, providing goal energy and protein without compromising fluid status. When at full maintenance, TPN typically provides a glucose infusion rate of 12-14 mg/kg/min over 24 hours, 2.5-3 g/kg protein, and 1 g/kg standard soy based lipid emulsion. Some programs are beginning to use SMOFlipid, containing soy, MCT, olive oil and fish oil, if additional lipid calories are desired, but currently this preparation is not licensed for Pediatric use in the United States.

In older children and teens, we start with the lower range of estimated enteral energy needs since metabolic demand for linear growth decreases with age. Patients with acute liver failure with encephalopathy may be intubated and sedated, altering metabolic demands. Indirect calorimetry studies may be useful if there is concern for under or over-feeding. Protein needs are also individualized in the context of impaired renal function and/or encephalopathy. Caution is advised in under dosing protein to prevent or treat hyperammonemia as this could contribute to catabolism and an overall rise in ammonia from endogenous protein catabolism. We recommend no less than 1.5-2 g/kg for infants and young children and 1 g/kg for older children and teens.

Table 3 Parenteral nutrition energy, protein and fluid goals for malnourished infants with ESLD (General guidelines per our institution).

3.2 Micronutrients

In patients with cholestasis, fat-soluble vitamin and zinc deficiencies are common. Vitamin E deficiency, which may lead to irreversible neuropathy, stunting, and neurodevelopmental disabilities, necessitates aggressive supplementation with appropriate doses of a water-miscible (Tocopherol polyethylene glycol succinate – TPGS) preparation. Standard vitamin E preparations are so poorly absorbed in the absence of bile flow, that this may be a difficult issue to manage given that many insurance providers refuse to pay for these special forms of vitamin E despite their therapeutic necessity. Trace elements are individually dosed in parenteral nutrition solutions to prevent copper and manganese toxicity. Heavy metals are usually excreted in the bile, and without bile flow accumulate and may be deposited in the basal ganglia resulting in movement disorders [2]. Routine supplementation of chromium is avoided at Seattle Children's given lack of evidence for deficiency with supportive evidence for toxicity in pediatric patients on long term PN [13]. Sodium is not limited in enteral nutrition for infants to ensure adequate nutrition for brain development anticipating losses from potential causes such as emesis or diuretics. However, restriction may be required for children and teens to decrease fluid retention. Potassium restriction may be required pre-transplant if treating ascites with a potassium sparing diuretic, such as spironolactone. However, if a potassium wasting diuretic (loop diuretic or thiazide) is also being given, serum potassium levels tend to normalize. General recommendations for supplements are outlined in Table 4.

Table 4 Micronutrient recommendations for infants and children with ESLD (general starting guidelines per our institution [1,2,13].

4. Post-Transplant Nutrition Support

Nutritional management of infants and children following liver transplant remains critical, with the ultimate goal of resolving or preventing malnutrition to promote wound healing, decrease infection risk, and decrease hospital length of stay. The nutrition plan varies in intensity depending on the phase: immediate post-operatively to time of initial discharge, then stable state for long term follow up.

4.1 Immediate Post-Operative Period

Several factors influence the chosen modality for nutrition support. Chiefly, nutrition status at time of transplant is paramount in estimating nutrition needs. Oral or enteral fed patients nourished at time of transplant may go without nutrition support up to 5 days post operatively. Older children and adolescents often resume adequate oral intake without nutrition support in the peri-operative period as opposed to infants and toddlers who may have developed oral aversion. Patients on parenteral nutrition pre-transplant will resume parenteral nutrition post-transplant (typically post-op-day 1 when hemodynamically stable), regardless of nutrition status until enteral feeding tolerance is established. Moderate to severely malnourished patients, regardless of nutrition support pre-transplant, will receive parenteral nutrition until enteral feeding tolerance is established. The type of biliary reconstruction is a predictor of timing for initiation of oral or enteral feeds [14]. This is helpful in estimating need and duration for parenteral nutrition (see Table 5)

Table 5 Anticipated days NPO for infants and children status post liver transplant by anastomosis type (our institutional experience, adapted from Texas Children’s Hospital Post Liver Transplant Nutrition Guidelines).

Surgical and medical interventions guide nutrition interventions. Frequent need for NPO status (e.g. return to operating room, radiology and ultrasound scans, extubation readiness trials) resulting in <80% of goal nutrition is an indication to extend parenteral nutrition support. Wound issues such as presence of wound vacuum, non-healing wounds or infection, require nutrition assessment every 5-7 days to determine adequacy of nutrition support. It is important to provide additional protein at 1.5-2 x RDA with liberal calorie provision using the upper range of estimated energy needs [15]. Acute kidney injury may occur post liver transplant [16], requiring fluid restriction and influencing ability to meet nutrition goals, especially with feeding intolerance of concentrated formula. Patients requiring continuous renal replacement therapy while awaiting for return of renal function tolerate higher volumes as the circuit can remove fluid to the desired balance. Typically patients will require 0.2 g/kg extra protein. Additional B vitamins are recommended when on renal replacement therapies when unable to take enteral supplements. For parenteral nutrition, vitamins are dosed according to recommendations in Table 6.

Table 6 Parenteral nutrition vitamins for patients on continuous renal replacement therapy post liver transplant [15].

4.2 Parenteral Nutrition

Parenteral nutrition is initiated when patients are hemodynamically stable, typically post op day 1 or 2. The initial goal is to prevent catabolism and provide a source of substrates for liver recovery, including glucose, protein and phosphorus [14]. Start with typical day one parenteral nutrition order, as the transplanted liver is new to the patient, and progress per standard advancements to goal. See Table 7 for macronutrient goal guidelines.

Table 7 Parenteral nutrition guidelines post liver transplant (per our institutional guidelines, adapted from ASPEN Table 29-3 p342) [14].

4.3 Enteral Nutrition

Patients transition to an age/developmentally appropriate diet when ready. Well nourished children not receiving nutrition support pre-transplant often resume a regular diet for age within a few days post-transplant, without need for tube feeding or parenteral nutrition. If tube feeding is needed, a standard formula preparation for age is appropriate for initiation of feeds with appropriate graft function. If graft function is delayed resulting in continued cholestasis, consider resuming pre-transplant formula for the high MCT content. Formula may be concentrated up to 30 kcal/oz for infants if needed for fluid restriction. Infants commonly have hyperkalemia due to Tacrolimus, therefor may require a low potassium formula until serum potassium stabilizes. Breast milk is preferred if available as potassium content is low. Children often receive 30 kcal/oz ready to feed formula. Teenagers tolerate higher calorie concentrations as needed, such as 45 kcal/oz. See Table 8 below for additional enteral recommendations. Bedside swallow evaluations are completed for infants and children at Seattle Children's that appear unsafe for oral feeds or have developed oral aversion. The goal is for all patients to transition off nutrition support post liver transplant.

Table 8 Enteral nutrition recommendations post liver transplant (guidelines per our institution).

4.4 Long-Term Nutrition Management

Infants and children are exposed to several potential complications post-liver transplant. The following is a list of nutritionally relevant issues and strategies to address them.

  • Food Safety: Families are educated on preventing food borne illness, including proper formula mixing and/or breast milk storage, food preparation and storage, and foods to avoid due to high risk for infection [14]. Patients are advised to avoid grapefruit and grapefruit containing beverages due to drug nutrient interaction with immunosuppressant impairing drug metabolism and leads to high drug levels.
  • Hyperglycemia/Post-Transplant diabetes: Most common in older adolescents and patients with Cystic Fibrosis. If blood sugars are consistently elevated, instruct on a ‘no concentrated sweets’ (i.e. no added sugar, avoidance of candy, desserts, syrups, regular soda, etc) diet. Advance to carbohydrate controlled meal plans and insulin therapy if necessary.
  • Hyperkalemia: commonly seen with use of calcineurin inhibitors such as Tacrolimus. Restrict potassium in the diet if serum levels consistently exceed 5-5.5 mEq/L. A potassium lowering medication may be needed, especially if dietary restriction is preventing adequate nutrition intake for weight gain and growth.
  • Hypomagnesemia: again related to the immunosuppressive medications. Magnesium supplementation is typically required to maintain serum levels, however oral magnesium is poorly absorbed and may cause loose stools. Allowing less than optimal magnesium levels may be appropriate if patients are experiencing uncomfortable side effects of magnesium supplementation.
  • Hyperlipidemia: Steroids and immunosuppressants, particularly mTOR inhibitors (Sirolimus, Everolimus) may increase cholesterol low density lipoprotein (LDL) and high density lipoprotein (HDL). Little is known of the relevance of hyperlipidemia in adolescents and young adults who are long-term survivors of solid organ transplants [17]. Atherosclerosis is a concern in adult transplant recipients, therefore long-term consequences in pediatrics warrant concern. Test Total cholesterol, Triglycerides, HDL and LDL levels annually.
  • Rejection: During periods of acute rejection, high doses of corticosteroids are frequently used. A low sodium and/or carbohydrate-counted diet may be indicated. High dose steroids increase protein catabolism, therefore ensure adequate protein intake during treatment of rejection.
  • Bone disorders: Bone mass may be reduced pre-transplant due to vitamin D deficiency and immobility or inactivity. High dose steroids in the post-transplant period may decrease bone formation, reduce bone strength, and predispose to pathologic fractures. Ensure adequate calcium, vitamin D and phosphorus. Supplementation may be indicated to achieve these goals and to maintain serum levels [14].
  • Food Allergies: immunosuppressive medications are associated with de novo food allergies, which is estimated to occur in 10-17% of young children [18]. Clinical signs/symptoms include rash and diarrhea. Radioallergosorbent (RAST) testing and eosinophilic infiltration on GI biopsy are both quite sensitive to determining presence of allergies, but neither are specific to type. The Registered Dietitian educates family on appropriate diet modifications once an allergen has been identified.
  • Overweight/Obesity: Dyslipidemia and impaired glucose tolerance are risks associated with overweight and obesity in pediatric patients. Catch up weight gain and accelerated weight velocity is expected post-liver transplant, however linear growth lags behind in trajectory, thus these patients are prone to overweight/obesity [19]. Complicating matters is the use of corticosteroids to treat rejection, leading to insulin resistance and metabolic syndrome like symptoms. Weight trajectory may normalize about 1 year post transplant, but not for all patients. Timely nutrition intervention should be provided by the dietitian and reiterated by team members, including education on healthy food choices, limiting sugary beverages, and ensuring structured meal and snack times.
  • Transplant for metabolic conditions: Protein metabolism may not normalize immediately post-transplant. Monitoring of amino acid levels may be relevant and require carnitine and arginine supplementation to help normalize the amino acid profile as the graft becomes fully functional.

4.5 Monitoring Over Time

Immediately post discharge, patients are seen twice weekly in Transplant clinic. Depending on complexity of care, the RD will see post-discharge patients at least once, if not twice weekly at the Transplant clinic appointments at this stage. Parenteral nutrition is discontinued before discharge with the exception of those receiving an isolated liver transplant for parenteral nutrition associate liver disease secondary to short gut syndrome. Weekly to monthly appointments continue as needed for patients receiving enteral nutrition support or on specialty formula (i.e. low potassium). Once on normal diet and growing appropriately, the dietitian will remain available to see the patient as needed, or upon request from the family or transplant team, for growth and feeding concerns as they arise (Figure 1B).

Figure 1 Pre and Post liver transplant pictures of a patient with diagnosis of Alpha-1 Antitrypsin Deficiency. A. Age 6 months prior to liver transplant. Note that a central line in place for parenteral nutrition initiated due to severe malnutrition. B. Aged 2 years a developmentally appropriate, well-nourished toddler. (Images supplied by parents and with full permission to publish).

5. Conclusions

The pathophysiologic causes of chronic liver disease and acute liver failure are varied, and each present different and unique nutritional challenges in both the pre and post-transplant period. While malnutrition is common in the child with liver failure, it is also treatable when approached with a multidisciplinary focus on identification of clinical symptoms. With aggressive efforts to correct nutritional deficiencies pre-transplant, patients are afforded a more favorable healing period, followed by improved post-transplant nutrition allowing for continued linear growth and improved quality of life.

Author Contributions

Melissa Mortensen – paper conception, writing and editing text; Christine Lundberg – paper conception and editing text; Simon Horslen - paper conception, writing and editing text.

Competing Interests

The authors have declared that no competing interests exist.


  1. Young S, Kwarta E, Azzam R, Sentongo T. Nutrition assessment and support in children with end-stage liver disease. Nutr Clin Pract. 2013; 28: 317-329. [CrossRef]
  2. Yang CH, Perumpail BJ, Yoo ER, Ahmed A, Kerner JA, Jr. Nutritional needs and support for children with chronic liver disease. Nutrients. 2017; 9: nu9101127. [CrossRef]
  3. Squires JE, McKiernan P, Squires RH. Acute liver failure: An update. Clin Liver Dis. 2018; 22: 773-805. [CrossRef]
  4. DeRusso PA, Ye W, Shepherd R, Haber BA, Shneider BL, Whitington PF, et al. Growth failure and outcomes in infants with biliary atresia: A report from the Biliary Atresia Research Consortium. Hepatology. 2007; 46: 1632-1638. [CrossRef]
  5. Venick RS, Farmer DG, Soto JR, Vargas J, Yersiz H, Kaldas FM, et al. One thousand pediatric liver transplants during thirty years: Lessons learned. J Am Coll Surg. 2018; 226: 355-366. [CrossRef]
  6. Hansen K, Horslen S. Metabolic liver disease in children. Liver Transpl. 2008; 14: 713-733. [CrossRef]
  7. Shepherd RW. Pre- and postoperative nutritional care in liver transplantation in children. J Gastroenterol Hepatol. 1996; 11: S7-S10. [CrossRef]
  8. Campos AC, Matias JE, Coelho JC. Nutritional aspects of liver transplantation. Curr Opin Clin Nutr Metab Care. 2002; 5: 297-307. [CrossRef]
  9. Loeb N, Owens JS, Strom M, Farassati F, Van Roestel K, Chambers K, et al. Long-term follow-up after pediatric liver transplantation: Predictors of growth. J Pediatr Gastroenterol Nutr. 2018; 66: 670-675. [CrossRef]
  10. Eidelman AI, Schanler RJ. Breastfeeding and the use of human milk. Pediatrics. 2012; 129: e827-e841. [CrossRef]
  11. Sullivan JS, Sundaram SS, Pan Z, Sokol RJ. Parenteral nutrition supplementation in biliary atresia patients listed for liver transplantation. Liver Transpl. 2012; 18: 120-128. [CrossRef]
  12. Wendel D, Mortensen M, Harmeson A, Shaffer ML, Hsu E, Horslen S. Resolving malnutrition with parenteral nutrition before liver transplant in biliary atresia. J Pediatr Gastroenterol Nutr. 2018; 66: 212-217. [CrossRef]
  13. Zemrani B, McCallum Z, Bines JE. Trace element provision in parenteral nutrition in children: One size does not fit all. Nutrients. 2018; 10: nu10111819. [CrossRef]
  14. Nucci AS, S. Katyal, N. Lytle, B. Organ transplantation. In: Corkins MR, Balint, J., Bobo E., Plogsted, S., Yaworski, J.A., editor. The ASPEN pediatric nutrition support core. Silver spring, MD.: American society of parenteral and enteral nutrition. 2010: 337-348.
  15. Thompson KL, Leu MG, Drummond KL, Popalisky J, Spencer SM, Lenssen PM. Nutrition interventions to optimize pediatric wound healing: An evidence-based clinical pathway. Nutr Clin Pract. 2014; 29: 473-482. [CrossRef]
  16. Deep A, Saxena R, Jose B. Acute kidney injury in children with chronic liver disease. Pediatr Nephrol. 2019; 34: 45-59. [CrossRef]
  17. Perito ER, Phelps A, Vase T, Feldstein VA, Lustig RH, Rosenthal P. Subclinical atherosclerosis in pediatric liver transplant recipients: Carotid and aorta intima-media thickness and their predictors. J Pediatr. 2018; 193: 119-127. [CrossRef]
  18. Hsu E, Horslen S. The emergence of eosinophilic disorders in pediatric transplant recipients. Pediatr Transplant. 2013; 17: 713-715. [CrossRef]
  19. Swenson SM, Perito ER. Weight gain trajectory predicts long-term overweight and obesity after pediatric liver transplant. J Pediatr Gastroenterol Nutr. 2019; 68: 89-95. [CrossRef]
Download PDF Download Citation
0 0